GAP BETWEEN PATIENT-REPORTED ESTIMATION ON FRACTURE RISK AND THE WHO ASSESSMENT TOOL (FRAX®) IN POSTMENOPAUSAL OSTEOPOROSIS

PM554

Parré M1, Hoeksma C1, Ersk K1, Bai P1, Bors K1, Clugston E1, Furi J1, Heacunz M1, Horváth B1, Karpátai S1, Bence I1, Korányi A1, Rápalthy I1, Tamás L1, Tóth E1, Gulácsi L1, Brodszky V1

1Corvinus University of Budapest, Budapest, Hungary; 2Semmelweis University, Budapest, Hungary; 3National Institute of Sport and Spa Dr. István Vajda, Győr, Hungary; 4Budafok Local Government Healthcare Service, Budapest, Hungary; 5Terézváros Health Care Service, Budapest, Hungary; 6Saint John's Hospital, Budapest, Hungary; 7Thermal Spa Hospital, Sopron-Balf, Hungary; 8Zugló Health Care Service, Budapest, Hungary; 9University of Pécs, Pécs, Hungary; 10Saint Borbála Hospital, Tatabánya, Hungary; 11Health Care Service Centre II of Székesfehérvár, Székesfehérvár, Hungary; 12Saint Francis' Hospital, Miskolc, Hungary; 13Flór Ferenc County Hospital, Kistarcsa, Hungary

OBJECTIVES: The FRAX® model recently developed by the WHO calculates 10-year probability of major osteoporotic and hip fracture, offering new basis for medical decision making and health economic analysis in osteoporosis (OP); [http://www.shef.ac.uk/FRAX/]. Patients’ ideas regarding fracture risk and longevity might influence their perception of 10-year fracture risk data and compliance, and as a consequence, successful implementation of FRAX® based thresholds in everyday OP care. Our aim was to study whether FRAX® data differ from OP patients’ and attendant specialists’ self-estimations on fracture risk. We also assessed expectations on longliving which is a crucial point to perceive the 10-year fracture risk projection of FRAX® relevant.

METHODS: In 2009 a cross-sectional survey was performed in 10 Hungarian rheumatology centres. Postmenopausal OP patients appearing on routine visit and switching to second line antiporotic drug were involved. Demographics, main clinical characteristics were registered. Patients’ estimation on 10-year fracture risk and longliving were surveyed. Patients’ expectations on patients’ perspectives were likely detected. FRAX® was calculated and matched with the estimations. RESULTS: 337 patients were involved, mean(SD): age 69.5(8.9)years, duration of OP care 6.7(5.1) years, lumbar T-score 3.17(0.82), femoral T-score -2.69(0.87), 133(59.4%) patients had OP fracture previously. Health status VAS was 59.17(9)mm. FRAX®-major OP fracture was 26(15.7%), patients estimated 32.7(25.8%), physicians marked 29.9(21.4%). Results for hip fracture were: FRAX® 12.6(15.31%), patients 26.7(25.3%)%, physicians 21.5(19.1)% (P < 0.01). Patients’ expected to live until age 82.4(8.2)years, physicians’ estimation was nearly same (82.5, SD7 yrs). Less than 10-year survival was expected by 55.2% of patients, and 57.1% of physicians. CONCLUSIONS: Both patients and physicians overestimate fracture risk, especially for hip. Patients often expect to live shorter than the time-frame of the fracture risk projection. These aspects should be highly considered in health communication and also in the application of the FRAX® method in clinical practice.

ANALYSIS ON THE POSSIBLE ASSOCIATION BETWEEN RHEUMATOID ARTHRITIS AND DIABETES MELLITUS TYPE 2

PM555

James P1, Fonseca JE1, Garcia EB1

1Faculty of Medicine, University of Lisbon, Lisbon, Portugal; 2BioEPI, Clinical and Translational Research Center, Lisbon, Portugal

OBJECTIVES: Rheumatoid Arthritis (RA), a chronic inflammatory disease, may predispose to the development of Type 2 Diabetes Mellitus (T2DM). We aimed to compare incidence rates of T2DM in RA versus non-RA populations and study the influencing factors. METHODS: The study population consisted of participants in the National Data Bank of the Russian Rheumatic Diseases (NRDRD), where patients with rheumatologic disorders completed semiannual questionnaires, from 1998 through 2008. Osteoarthritis (OA) patients were used as controls. T2DM was determined based on self-reports of disease and on the use of hypoglycemic medication. The association between RA and T2DM was investigated using COX logistic regressions adjusted for relevant clinical and demographic covariates. RESULTS: A total of 14,481 participants diagnosed with RA (79.5% female; mean age 58.1 years) and 3,441 participants diagnosed with OA (84.5% female; mean age 61.6 years) were followed during 69,943 person-years. RA subjects had lower Body Mass Index (BMI) and less major comorbidities than controls. In patients with RA the T2DM incidence rate was 10 per 1000 person-years, while the incidence rate for OA was 15 per 1000 person-years. Both rates are superior to most estimates calculated among the US population. However, the covariate-adjusted risk of T2DM in patients with RA versus OA was not significant (HR = 0.94, 95% CI: 0.79-1.12, p = NS). Male gender, age, BMI, non-caucasian ethnicity, major comorbidities, low education level and prednisone intake were significantly associated with the incidence of T2DM. Some RA drugs had a clear protective role on T2DM, mainly methotrexate (19% risk reduction; p = 0.022) and hydroxychloroquine (47% risk reduction; P < 0.001), CONCLUSIONS: RA per se is not associated with increased risk of T2DM. Both RA and OA are associated with known T2DM risk factors, such as BMI and some comorbidities, increasing the incidence rates of T2DM. Some drugs for RA treatment have a significant protective effect on the T2DM risk.

DETERMINING THE OPTIMAL TIMING FOR TOTAL KNEE REPLACEMENT

PM556

Ke Y1, Lo NN2, Yeo SJ3, Yang KY4, Yeo WW5, Chong HC6, Thumbi J7

1National University of Singapore, Singapore; 2Singapore General Hospital, Singapore

OBJECTIVES: Total knee replacement (TKR) is a commonly used surgical procedure for patients with severe joint damage caused by arthritis; however, there remain difficulties in establishing criteria to define the optimal timing for TKR. The aim of this study was to identify the preoperative threshold HRQoL scores that were associated with better postoperative outcomes and those associated with greater improvement. METHODS: Data were collected from 1715 patients undergoing TKR between 2001 and 2006. Patients were interviewed at baseline and at 6 months and 2 years after surgery. At all three interview sessions, patients were asked to complete the Short-Form (SF-36) and the Oxford Knee Score (OKS). As physical function and pain have been identified as the key domains in osteoarthritis, the OKS and the physical functioning (PF) and bodily pain (BP) scales of the SF-36 were selected as the outcome measures of this study. Summary statistics were computed for preoperative, postoperative, and improvement in outcome scores. Visual inspection of the simple error bar charts were used to identify the threshold preoperative scores that were associated with better postoperative scores and those associated with more improvement. RESULTS: Patients with poorer preoperative HRQoL had worse postoperative outcomes but experienced greater improvement after TKR compared to those with better preoperative HRQoL. The highest postoperative PF scores are associated with a preoperative PF score of 30 points and above, whereas the baseline threshold OKS score was between 35 and 40 points, a baseline PF score of 30 points and an OKS score of >40 points are associated with the greatest improvement. No clear leveling off pattern was observed in the BP scores. CONCLUSIONS: PF and OKS threshold scores associated with optimal outcomes of TKR were identified in this study. Future research is needed to examine the predictive value of the scores identified in improving patients’ postoperative outcomes.

HEALTH-RELATED QUALITY OF LIFE AFTER TOTAL KNEE REPLACEMENT OR UNCOMPARTMENTAL KNEE ARTHROPLASTY IN AN ASIAN URBAN POPULATION

PM557

Ko Y1, Narayansamy S2, Wise HL1, Lo NN1, Yeo SJ1, Yang KY1, Yeo WW1, Chong HC1, Thumbi J2

1National University of Singapore, Singapore; 2Singapore General Hospital, Singapore

OBJECTIVES: To examine health-related quality of life (HRQoL) following total knee replacement (TKR) or uncompartmental knee arthroplasty (UKA). METHODS: Asian adult patients undergoing either TKR or UKA in a hospital of Singapore between 2001 and 2006 were interviewed before surgery and 6 and 24 months post-operatively to obtain demographic information and HRQoL scores using the Short-Form (SF-36) and the Oxford Knee Score (OKS). RESULTS: Data were collected from 2243, 1715, and 1113 patients at baseline, 6, and 24 months, respectively. TKR patients had a lower preoperative score than UKA patients on OKS and four subscales of the SF-36 (p < 0.01). Both TKR and UKA patients’ OKS and SF-36 subscale scores improved six months postoperatively except in the general health domain. SF-36 role physical (RP) and bodily pain (BP) scores showed the most improvement (40.9 and 33.0 points in TKR and 36.9 and 31.4 points in UKA patients, respectively). The most substantial improvements between baseline and two years after surgery were in the physical domains of HRQoL (RP, BP, and physical functioning (PF)). In addition, in both groups, five domains of SF-36 (RP, BF, PF, social functioning, and role limitations due to emotional problems) reached the proposed minimal clinically important difference points. TKR patients’ SF-36 and OKS scores were not significantly different from those of UKA patients two years after surgery, except PF scores. Multiple regression analysis adjusting for sociodemographics showed that baseline scores were a significant predictor of the postoperative scores of OKS and all SF-36 subscales (p < 0.01), whereas the type of surgery was not associated with the postoperative scores. CONCLUSIONS: Both TKR and UKA patients experienced significant improvements in HRQoL, particularly in the RP and BF domains. After controlling for potential confounding variables, the type of surgery was not a significant predictor of patients’ postoperative HRQoL scores.

CLINICAL OUTCOMES AND CHANGES IN QUALITY OF LIFE IN WOMEN WITH OSTEOPOROSIS TREATED WITH TERIPARATIDE: 36 MONTH RESULTS OF THE FRENCH PATIENTS PARTICIPATING IN THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)

PM558

Rajbaum G1, Tcherny-Lessenot S2, Liu-Leage S2, Gehchan N2, Barrett A3

1National University of Singapore, Singapore; 2Singapore General Hospital, Singapore

OBJECTIVES: To describe back pain, and HRQoL in postmenopausal women with osteoporosis treated with teriparatide (Forsteo®) in France. METHODS: European, prospective, observational study of 36 months duration (18-month active treatment phase and 18-month post-treatment follow up) in postmenopausal women with osteoporosis who initiated teriparatide. HRQoL measured by EQ-5D and back pain measured by a Visual Analogue Scale (VAS) and a questionnaire were collected at each follow-up visit. RESULTS: Among 309 patients enrolled in France (18.8% of the total EFOS cohort), 290 (94.5%) had any follow-up data, and 201 (65.0%) completed the last post-treatment visit. At baseline, patients were 73.8 (7.4) years old (mean (SD)),